Agents such as the antimetabolites 5-fluorouracil (5FU) and mitomycin-C (MMC) have revolutionised glaucoma surgery in patients with a high risk of surgical failure. However, vision threatening complications can be associated with the use of these agents. Changes in antimetabolites application during and after the surgery can increase the safety and reduce the complications while maintaining effectiveness.